

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** ██████████  
**Sex:** ██████  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 01/01/2017 12:34

**CBFB-MYH11 inv(16) Detection, Quantitative**

ARUP test code 2011114

CBFB-MYH11 Source Bone Marrow  
CBFB-MYH11 Result Detected: Type D

CBFB-MYH11 fusion transcripts (type D) were detected by RT-qPCR. This indicates the presence of inv(16)/t(16;16) positive cells in the sample.  
This result has been reviewed and approved by ██████████

**INTERPRETIVE INFORMATION: CBFB-MYH11 inv(16) Quantitative**

This test is designed to detect and quantify CBFB-MYH11 fusion transcripts (type A, D or E) which result from inv(16)/t(16;16);CBFB-MYH11, a recurrent genetic abnormality found in a subset of patients with acute myeloid leukemia.

**Methodology:**

Patient RNA is isolated, reverse transcribed into cDNA, and amplified using primers specific for the CBFB and MYH11 genes. A normalized ratio is calculated representing CBFB-MYH11 transcripts / ABL1 transcripts.

**Limitations:**

Translocations involving other genes or gene partners will not be detected.  
The limit of quantitation for this test is 0.0001 (NCN).

Results of this test must always be interpreted within the patient's clinical context and in conjunction with other relevant data. Results should not be used alone for a diagnosis of malignancy.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

CBFB-MYH11/ABL1 Ratio 0.00263

VERIFIED/REPORTED DATES

| Procedure         | Accession     | Collected            | Received             | Verified/Reported    |
|-------------------|---------------|----------------------|----------------------|----------------------|
| CBFB-MYH11 Source | 22-133-140319 | 5/13/2022 1 20:00 PM | 5/14/2022 8:25:23 PM | 5/18/2022 3:44 00 PM |

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

|                       |               |                      |                      |                      |
|-----------------------|---------------|----------------------|----------------------|----------------------|
| CBFB-MYH11 Result     | 22-133-140319 | 5/13/2022 1 20:00 PM | 5/14/2022 8:25:23 PM | 5/18/2022 3:44 00 PM |
| CBFB-MYH11/ABL1 Ratio | 22-133-140319 | 5/13/2022 1 20:00 PM | 5/14/2022 8:25:23 PM | 5/18/2022 3:44 00 PM |

END OF CHART

---

H=High, L=Low, \*=Abnormal, C=Critical

---

Unless otherwise indicated, testing performed at:

**ARUP LABORATORIES | 800-522-2787 | aruplab.com**  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 22-133-140319  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 7/20/2022 6:51:50 AM